Results from Biovitrum's Phase II Clinical Trial of Novel PainTreatment is expected to be presented in beginning of second quarter2008

Biovitrum evaluates a novel  method for treating pain  in a phase  II
clinical trial. The recruitment of patients to the study has now been
completed and the results are expected to be presented already  early
second quarter 2008.

Comments Biovitrum's CEO Martin Nicklasson:
The study  has been  completed  in an  excellent manner  without  any
delays, which is very positive for such a large trial.

The treatment aims at  neuropathic pain, which is  a chronic form  of
pain resulting from  nerve injuries. Contrary  to current  treatments
that act  in the  brain,  Biovitrum's substance  is expected  to  act
peripherally, directly in the  injured nerve. There  is a very  large
unmet  medical  need  in  this  area.  The  market  is  estimated  to
approximately SEK 18 billion.

The drug candidate presently tested  is a substance that activates  a
protein  (adenosine  receptor  2A)  that,  among  other  things,   is
responsible for reducing inflammations. The substance is expected  to
have a pain-alleviating effect  by reducing inflammation directly  in
the damaged nerve whereas available treatments mainly are represented
by drugs acting in the brain. The efficacy of these drugs is  limited
and the risk is high for  side effects such as dizziness, nausea  and
somnolence. As  Biovitrum's  substance acts  at  the site  of  injury
peripherally in the body, the risk  is reduced for this type of  side
effects  related  to  the  central  nervous  system.  This  therefore
represents a novel treatment with  both reduced risk of side  effects
and the potential for analgesic as well as anti-inflammatory effects.


For more information, contact:

Biovitrum AB (publ)

Martin Nicklasson,
CEO
Phone: +46 8 697 20 00
[email protected]

Anna Karin Källén, Vice President, Corporate Communications
Phone: +46 8 697 20 85, Cell phone: +46 73 433 20 85
[email protected]


Facts to the editor

About neuropathic pain
Neuropathic pain is a form of  chronic pain that stems from  injuries
to  the   sensory  nerves,   often  associated   with  diabetes   and
inflammatory injuries. Even  though inflammation is  the body's  main
defense against infection,  irritation and  injury, inflammation  can
also be linked to development  of chronic pain. In inflammations  the
pH-value decreases in the injured tissue. Biovitrum's drug  candidate
makes  use  of  this  condition  and  acts  only  at  the  lower  pH.
Consequently, the action of the substance is directed to the site  of
injury, thereby  reducing the  risk of  side effects.  The number  of
people who suffer  from neuropathic  pain worldwide  is estimated  at
almost 38 million. Currently  available drugs, represented mainly  by
antiepileptics, have limited  efficacy and  entail significant  risks
for side  effects  related to  the  central nervous  system  such  as
dizziness,   nausea   and   somnolence.   Nevertheless,   the   total
pharmaceuticals market for  neuropathic pain is  to day estimated  to
approximately SEK 18 billion

About the Phase II-study
In the  study,  which is  randomized  (patients are  divided  between
experimental and  control groups  at random)  and  placebo-controlled
(results will be compared with patients treated with an agent without
any actual  medicinal effect;  the control  group), the  compound  is
administered three times daily for four weeks. The primary  objective
is to assess the efficacy of BVT.115959 using pain estimation scales.
Among the secondary objectives are additional assessments of pain and
perceived sleep disturbances, quality of life and mood stability. The
study is being conducted at 23 clinics in Germany, the Czech Republic
and  South  Africa.  BVT.115959  has  previously  completed   initial
clinical trials (phase  I) in a  total of 67  healthy volunteers.  In
these studies the compound was found to be safe and tolerable.


About Biovitrum
Biovitrum is one of the  largest biopharma companies in Europe.  With
operations in Sweden and  in the UK  Biovitrum conducts research  and
develops pharmaceuticals for unmet medical needs both for  conditions
that affect  smaller patient  populations  and for  common  diseases.
Biovitrum has  currently  a broad  and  balanced R&D  portfolio  with
several projects in clinical and  preclinical phases for a number  of
well defined specialist  indications as well  as for common  diseases
within obesity,  diabetes,  inflammation,  eye  and  blood  diseases.
Biovitrum develops and produces protein-based drugs on a  contractual
basis and markets a range of specialist pharmaceuticals primarily  in
the Nordic countries. Biovitrum has revenues of approximately SEK 1.2
billion and around 500 employees. Biovitrum's share is listed on  the
OMX Nordic Exchange in Stockholm  since September 15, 2006. For  more
information see http://www.biovitrum.com.